BRASILIA (Reuters) – Brazil’s Butantan Institute biomedical center this week received the first doses of China’s Sinovac vaccine against COVID-19, its director, Dimas Covas, said on Tuesday, speaking remotely in a congressional hearing.
Covas said the preliminary results of the trials Butantan is conducting in Brazil indicate that the vaccine, called CoronaVac, has an excellent safety profile. He said Butantan expects to have 46 million doses ready for use in January.
(Reporting by Anthony Boadle and Maria Carolina Marcello; editing by Jonathan Oatis)
